Pub Date : 2023-12-22eCollection Date: 2023-01-01DOI: 10.1590/0074-02760230143
Adrián Rodríguez-Carlos, Yolanda Jacobo-Delgado, Alan Orlando Santos-Mena, Mariana H García-Hernández, Luis Adrian De Jesus-Gonzalez, Edgar E Lara-Ramirez, Bruno Rivas-Santiago
Background: Tuberculosis (TB) is a major public health problem, which has been aggravated by the alarming growth of drug-resistant tuberculosis. Therefore, the development of a safer and more effective treatment is needed.
Objectives: The aim of this work was repositioning and evaluate histone deacetylases (HDAC) inhibitors- based drugs with potential antimycobacterial activity.
Methods: Using an in silico pharmacological repositioning strategy, three molecules that bind to the catalytic site of histone deacetylase were selected. Pneumocytes type II and macrophages were infected with Mycobacterium tuberculosis and treated with pre-selected HDAC inhibitors (HDACi). Subsequently, the ability of each of these molecules to directly promote the elimination of M. tuberculosis was evaluated by colony-forming unit (CFU)/mL. We assessed the expression of antimicrobial peptides and respiratory burst using reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Findings: Aminoacetanilide (ACE), N-Boc-1,2-phenylenediamine (N-BOC), 1,3-Diphenylurea (DFU), reduce bacillary loads in macrophages and increase the production of β-defensin-2, LL-37, superoxide dismutase (SOD) 3 and inducible nitric oxide synthase (iNOS). While only the use of ACE in type II pneumocytes decreases the bacterial load through increasing LL-37 expression. Furthermore, the use of ACE and rifampicin inhibited the survival of intracellular multi-drug resistance M. tuberculosis.
Main conclusions: Our data support the usefulness of in silico approaches for drug repositioning to provide a potential adjunctive therapy for TB.
背景:结核病(TB)是一个重大的公共卫生问题,耐药性结核病的惊人增长加剧了这一问题。因此,需要开发一种更安全、更有效的治疗方法:本研究旨在重新定位和评估基于组蛋白去乙酰化酶(HDAC)抑制剂的具有潜在抗结核活性的药物:方法:采用硅药理学重新定位策略,筛选出三种与组蛋白去乙酰化酶催化位点结合的分子。用结核分枝杆菌感染 II 型肺炎细胞和巨噬细胞,并用预先选择的 HDAC 抑制剂(HDACi)进行处理。随后,通过菌落形成单位(CFU)/毫升来评估这些分子直接促进消除结核杆菌的能力。我们使用反转录定量聚合酶链反应(RT-qPCR)评估了抗菌肽和呼吸爆发的表达:氨基乙酰苯胺(ACE)、N-叔丁氧羰基-1,2-苯二胺(N-BOC)、1,3-二苯基脲(DFU)可减少巨噬细胞中的细菌负荷,并增加β-防御素-2、LL-37、超氧化物歧化酶(SOD)3和诱导型一氧化氮合酶(iNOS)的产生。只有在 II 型肺细胞中使用 ACE 才能通过增加 LL-37 的表达来减少细菌负荷。此外,使用 ACE 和利福平可抑制细胞内多重耐药结核杆菌的存活:主要结论:我们的数据支持采用硅学方法对药物进行重新定位,从而为结核病提供一种潜在的辅助疗法。
{"title":"Histone deacetylase (HDAC) inhibitors- based drugs are effective to control Mycobacterium tuberculosis infection and promote the sensibility for rifampicin in MDR strain.","authors":"Adrián Rodríguez-Carlos, Yolanda Jacobo-Delgado, Alan Orlando Santos-Mena, Mariana H García-Hernández, Luis Adrian De Jesus-Gonzalez, Edgar E Lara-Ramirez, Bruno Rivas-Santiago","doi":"10.1590/0074-02760230143","DOIUrl":"10.1590/0074-02760230143","url":null,"abstract":"<p><strong>Background: </strong>Tuberculosis (TB) is a major public health problem, which has been aggravated by the alarming growth of drug-resistant tuberculosis. Therefore, the development of a safer and more effective treatment is needed.</p><p><strong>Objectives: </strong>The aim of this work was repositioning and evaluate histone deacetylases (HDAC) inhibitors- based drugs with potential antimycobacterial activity.</p><p><strong>Methods: </strong>Using an in silico pharmacological repositioning strategy, three molecules that bind to the catalytic site of histone deacetylase were selected. Pneumocytes type II and macrophages were infected with Mycobacterium tuberculosis and treated with pre-selected HDAC inhibitors (HDACi). Subsequently, the ability of each of these molecules to directly promote the elimination of M. tuberculosis was evaluated by colony-forming unit (CFU)/mL. We assessed the expression of antimicrobial peptides and respiratory burst using reverse transcription-quantitative polymerase chain reaction (RT-qPCR).</p><p><strong>Findings: </strong>Aminoacetanilide (ACE), N-Boc-1,2-phenylenediamine (N-BOC), 1,3-Diphenylurea (DFU), reduce bacillary loads in macrophages and increase the production of β-defensin-2, LL-37, superoxide dismutase (SOD) 3 and inducible nitric oxide synthase (iNOS). While only the use of ACE in type II pneumocytes decreases the bacterial load through increasing LL-37 expression. Furthermore, the use of ACE and rifampicin inhibited the survival of intracellular multi-drug resistance M. tuberculosis.</p><p><strong>Main conclusions: </strong>Our data support the usefulness of in silico approaches for drug repositioning to provide a potential adjunctive therapy for TB.</p>","PeriodicalId":18469,"journal":{"name":"Memorias do Instituto Oswaldo Cruz","volume":"118 ","pages":"e230143"},"PeriodicalIF":2.8,"publicationDate":"2023-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10740574/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138830409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-15eCollection Date: 2023-01-01DOI: 10.1590/0074-02760230115
Ana Carolina Bastos de Lima, Veronica Gonçalves Mendes, Roberto Rodrigues Ferreira, Lindice Mitie Nisimura, Samuel Iwao Maia Horita, Henrique H Veloso, Andréa R Costa, Gilberto Marcelo S da Silva, Luiz Henrique C Sangenis, Marcelo T Holanda, Lorena Rimolo, Ademir B Cunha, Luciana Ribeiro Garzoni, Alejandro Marcel Hasslocher-Moreno, Mauro Felippe F Mediano, Otacílio da Cruz Moreira, Constança Britto, Roberto M Saraiva
Background: A positive Trypanosoma cruzi polymerase chain reaction (PCR) is associated with a worse prognosis in patients with chronic Chagas disease (CD).
Objectives: To study the association of clinical, electrocardiographic, and echocardiographic characteristics and biomarker blood levels with positive T. cruzi PCR in chronic CD.
Methods: This is a single-centre observational cross-sectional study. Positive T. cruzi PCR association with clinical, electrocardiographic, and echocardiographic characteristics, and biomarker blood levels were studied by logistic regression analysis. p values < 0.05 were considered significant.
Findings: Among 333 patients with chronic CD (56.4% men; 62 ± 10 years), T. cruzi PCR was positive in 41.1%. Stepwise multivariate logistic regression showed an independent association between positive T. cruzi PCR and diabetes mellitus {odds ratio (OR) 0.53 [95% confidence interval (CI) 0.30-0.93]; p = 0.03}, right bundle branch block [OR 1.78 (95% CI 1.09-2.89); p = 0.02], and history of trypanocidal treatment [OR 0.13 (95% CI 0.04-0.38); p = 0.0002]. Among patients with a history of trypanocidal treatment (n = 39), only four (10%) patients had a positive T. cruzi PCR.
Main conclusions: Among several studied parameters, only diabetes mellitus, right bundle branch block, and history of trypanocidal treatment showed an independent association with positive T. cruzi PCR. History of trypanocidal treatment was a strong protective factor against a positive T. cruzi PCR.
背景:克氏锥虫聚合酶链反应(PCR)阳性与慢性南美锥虫病(CD)患者的预后有关:克鲁斯锥虫聚合酶链反应(PCR)阳性与慢性恰加斯病(CD)患者预后较差有关:研究慢性南美锥虫病患者的临床、心电图和超声心动图特征以及血液中生物标志物水平与南美锥虫聚合酶链反应阳性的相关性:这是一项单中心观察性横断面研究。通过逻辑回归分析研究了T. cruzi PCR阳性与临床、心电图、超声心动图特征以及血液中生物标志物水平的关系:在 333 名慢性 CD 患者(56.4% 为男性;62 ± 10 岁)中,41.1% 的患者 T. cruzi PCR 呈阳性。逐步多变量逻辑回归显示,T. cruzi PCR 阳性与糖尿病{多态比 (OR) 0.53 [95% 置信区间 (CI) 0.30-0.93]; p = 0.03}、右束支传导阻滞[OR 1.78 (95% CI 1.09-2.89); p = 0.02]和杀锥虫治疗史[OR 0.13 (95% CI 0.04-0.38); p = 0.0002]之间存在独立关联。在有锥虫治疗史的患者(39 人)中,只有 4 人(10%)的 T. cruzi PCR 呈阳性:主要结论:在几项研究参数中,只有糖尿病、右束支传导阻滞和杀锥虫治疗史与 T. cruzi PCR 阳性有独立关联。杀锥虫治疗史是防止 T. cruzi PCR 阳性的一个强有力的保护因素。
{"title":"Predictors of Trypanosoma cruzi PCR positivity in patients with chronic Chagas disease.","authors":"Ana Carolina Bastos de Lima, Veronica Gonçalves Mendes, Roberto Rodrigues Ferreira, Lindice Mitie Nisimura, Samuel Iwao Maia Horita, Henrique H Veloso, Andréa R Costa, Gilberto Marcelo S da Silva, Luiz Henrique C Sangenis, Marcelo T Holanda, Lorena Rimolo, Ademir B Cunha, Luciana Ribeiro Garzoni, Alejandro Marcel Hasslocher-Moreno, Mauro Felippe F Mediano, Otacílio da Cruz Moreira, Constança Britto, Roberto M Saraiva","doi":"10.1590/0074-02760230115","DOIUrl":"10.1590/0074-02760230115","url":null,"abstract":"<p><strong>Background: </strong>A positive Trypanosoma cruzi polymerase chain reaction (PCR) is associated with a worse prognosis in patients with chronic Chagas disease (CD).</p><p><strong>Objectives: </strong>To study the association of clinical, electrocardiographic, and echocardiographic characteristics and biomarker blood levels with positive T. cruzi PCR in chronic CD.</p><p><strong>Methods: </strong>This is a single-centre observational cross-sectional study. Positive T. cruzi PCR association with clinical, electrocardiographic, and echocardiographic characteristics, and biomarker blood levels were studied by logistic regression analysis. p values < 0.05 were considered significant.</p><p><strong>Findings: </strong>Among 333 patients with chronic CD (56.4% men; 62 ± 10 years), T. cruzi PCR was positive in 41.1%. Stepwise multivariate logistic regression showed an independent association between positive T. cruzi PCR and diabetes mellitus {odds ratio (OR) 0.53 [95% confidence interval (CI) 0.30-0.93]; p = 0.03}, right bundle branch block [OR 1.78 (95% CI 1.09-2.89); p = 0.02], and history of trypanocidal treatment [OR 0.13 (95% CI 0.04-0.38); p = 0.0002]. Among patients with a history of trypanocidal treatment (n = 39), only four (10%) patients had a positive T. cruzi PCR.</p><p><strong>Main conclusions: </strong>Among several studied parameters, only diabetes mellitus, right bundle branch block, and history of trypanocidal treatment showed an independent association with positive T. cruzi PCR. History of trypanocidal treatment was a strong protective factor against a positive T. cruzi PCR.</p>","PeriodicalId":18469,"journal":{"name":"Memorias do Instituto Oswaldo Cruz","volume":"118 ","pages":"e230115"},"PeriodicalIF":2.8,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10727046/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138830410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-27eCollection Date: 2023-01-01DOI: 10.1590/0074-02760220225
Marina Neves Gonçalves, Daiana Silva Lopes, Samuel Cota Teixeira, Thaise Lara Teixeira, Vitor de Freitas, Tássia Rafaella Costa, Sarah Natalie Cirilo Gimenes, Isabella Mitie de Camargo, Guilherme de Souza, Marcelo Santos da Silva, Fernanda Van Petten de Vasconcelos Azevedo, Kathleen Fernandes Grego, Luísa Carregosa Santos, Vinícius Queiroz Oliveira, Claudio Vieira da Silva, Renata Santos Rodrigues, Kelly Aparecida Geraldo Yoneyama, Patricia Bianca Clissa, Veridiana de Melo Rodrigues
Background: Leishmaniasis, a neglected disease caused by the parasite Leishmania, is treated with drugs associated with high toxicity and limited efficacy, in addition to constant reports of the emergence of resistant parasites. In this context, snake serums emerge as good candidates since they are natural sources with the potential to yield novel drugs.
Objectives: We aimed to show the antileishmanial effects of γCdcPLI, a phospholipase A2 inhibitor from Crotalus durissus collilineatus snake serum, against Leishmania (Leishmania) amazonensis.
Methods: Promastigotes forms were exposed to γCdcPLI, and we assessed the parasite viability and cell cycle, as well as invasion and proliferation assays.
Findings: Despite the low cytotoxicity effect on macrophages, our data indicate that γCdcPLI has a direct effect on parasites promoting an arrest in the G1 phase and reduction in the G2/M phase at the highest dose tested. Moreover, this PLA2 inhibitor reduced the parasite infectivity when promastigotes were pre-treated. Also, we demonstrated that the γCdcPLI treatment modulated the host cell environment impairing early and late steps of the parasitism.
Main conclusions: γCdcPLI is an interesting tool for the discovery of new essential targets on the parasite, as well as an alternative compound to improve the effectiveness of the leishmaniasis treatment.
{"title":"Antileishmanial effects of γCdcPLI, a phospholipase A2 inhibitor from Crotalus durissus collilineatus snake serum, on Leishmania (Leishmania) amazonensis.","authors":"Marina Neves Gonçalves, Daiana Silva Lopes, Samuel Cota Teixeira, Thaise Lara Teixeira, Vitor de Freitas, Tássia Rafaella Costa, Sarah Natalie Cirilo Gimenes, Isabella Mitie de Camargo, Guilherme de Souza, Marcelo Santos da Silva, Fernanda Van Petten de Vasconcelos Azevedo, Kathleen Fernandes Grego, Luísa Carregosa Santos, Vinícius Queiroz Oliveira, Claudio Vieira da Silva, Renata Santos Rodrigues, Kelly Aparecida Geraldo Yoneyama, Patricia Bianca Clissa, Veridiana de Melo Rodrigues","doi":"10.1590/0074-02760220225","DOIUrl":"10.1590/0074-02760220225","url":null,"abstract":"<p><strong>Background: </strong>Leishmaniasis, a neglected disease caused by the parasite Leishmania, is treated with drugs associated with high toxicity and limited efficacy, in addition to constant reports of the emergence of resistant parasites. In this context, snake serums emerge as good candidates since they are natural sources with the potential to yield novel drugs.</p><p><strong>Objectives: </strong>We aimed to show the antileishmanial effects of γCdcPLI, a phospholipase A2 inhibitor from Crotalus durissus collilineatus snake serum, against Leishmania (Leishmania) amazonensis.</p><p><strong>Methods: </strong>Promastigotes forms were exposed to γCdcPLI, and we assessed the parasite viability and cell cycle, as well as invasion and proliferation assays.</p><p><strong>Findings: </strong>Despite the low cytotoxicity effect on macrophages, our data indicate that γCdcPLI has a direct effect on parasites promoting an arrest in the G1 phase and reduction in the G2/M phase at the highest dose tested. Moreover, this PLA2 inhibitor reduced the parasite infectivity when promastigotes were pre-treated. Also, we demonstrated that the γCdcPLI treatment modulated the host cell environment impairing early and late steps of the parasitism.</p><p><strong>Main conclusions: </strong>γCdcPLI is an interesting tool for the discovery of new essential targets on the parasite, as well as an alternative compound to improve the effectiveness of the leishmaniasis treatment.</p>","PeriodicalId":18469,"journal":{"name":"Memorias do Instituto Oswaldo Cruz","volume":"118 ","pages":"e220225"},"PeriodicalIF":2.8,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690931/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138451879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-03eCollection Date: 2023-01-01DOI: 10.1590/0074-02760230122
Paula Alves, Vanessa Emmel, Gustavo Stefanoff, Flavia Krsticevic, Joaquín Ezpeleta, Javier Murillo, Elizabeth Tapia, Edson Delatorre, Eliana Abdelhay, Rocio Hassan
Background: Epstein-Barr virus (EBV) is a human gammaherpesvirus etiologically linked to several benign and malignant diseases. EBV-associated malignancies exhibit an unusual global distribution that might be partly attributed to virus and host genetic backgrounds.
Objectives: To assemble a new genome of EBV (CEMO3) from a paediatric Burkitt's lymphoma from Rio de Janeiro State (Southeast Brazil). In addition, to perform global phylogenetic analysis using complete EBV genomes, including CEMO3, and investigate the genetic relationship of some South American (SA) genomes through EBV subgenomic targets.
Methods: CEMO3 was sequenced through next generation sequencing and its coverage and gaps were corrected through the Sanger method. CEMO3 and 67 EBV genomes representing diverse geographic regions were evaluated through maximum likelihood phylogenetic analysis. Further, the polymorphism of subgenomic regions of some SA EBV genomes were assessed.
Findings: The whole bulk tumour sequencing yielded 23,217 reads related to EBV, which 172,713 base pairs of the newly EBV genome CEMO3 was assembled. The CEMO3 and most SA EBV genomes clustered within the SA subclade closely related to the African Raji strain, forming the South American/Raji clade. Notably, these Raji-related genomes exhibit significant genetic diversity, characterised by distinctive synapomorphies at some gene levels absent in the original Raji strain.
Conclusion: The CEMO3 represents a new South American EBV genome assembled. Albeit the majority of EBV genomes from SA are Raji-related, it harbours a high diversity different from the original Raji strain.
{"title":"Unique synapomorphies and high diversity in South American Raji-related Epstein-Barr virus genomes.","authors":"Paula Alves, Vanessa Emmel, Gustavo Stefanoff, Flavia Krsticevic, Joaquín Ezpeleta, Javier Murillo, Elizabeth Tapia, Edson Delatorre, Eliana Abdelhay, Rocio Hassan","doi":"10.1590/0074-02760230122","DOIUrl":"10.1590/0074-02760230122","url":null,"abstract":"<p><strong>Background: </strong>Epstein-Barr virus (EBV) is a human gammaherpesvirus etiologically linked to several benign and malignant diseases. EBV-associated malignancies exhibit an unusual global distribution that might be partly attributed to virus and host genetic backgrounds.</p><p><strong>Objectives: </strong>To assemble a new genome of EBV (CEMO3) from a paediatric Burkitt's lymphoma from Rio de Janeiro State (Southeast Brazil). In addition, to perform global phylogenetic analysis using complete EBV genomes, including CEMO3, and investigate the genetic relationship of some South American (SA) genomes through EBV subgenomic targets.</p><p><strong>Methods: </strong>CEMO3 was sequenced through next generation sequencing and its coverage and gaps were corrected through the Sanger method. CEMO3 and 67 EBV genomes representing diverse geographic regions were evaluated through maximum likelihood phylogenetic analysis. Further, the polymorphism of subgenomic regions of some SA EBV genomes were assessed.</p><p><strong>Findings: </strong>The whole bulk tumour sequencing yielded 23,217 reads related to EBV, which 172,713 base pairs of the newly EBV genome CEMO3 was assembled. The CEMO3 and most SA EBV genomes clustered within the SA subclade closely related to the African Raji strain, forming the South American/Raji clade. Notably, these Raji-related genomes exhibit significant genetic diversity, characterised by distinctive synapomorphies at some gene levels absent in the original Raji strain.</p><p><strong>Conclusion: </strong>The CEMO3 represents a new South American EBV genome assembled. Albeit the majority of EBV genomes from SA are Raji-related, it harbours a high diversity different from the original Raji strain.</p>","PeriodicalId":18469,"journal":{"name":"Memorias do Instituto Oswaldo Cruz","volume":"118 ","pages":"e230122"},"PeriodicalIF":2.8,"publicationDate":"2023-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71483359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-27eCollection Date: 2023-01-01DOI: 10.1590/0074-02760230081
Érica Lourenço Fonseca, Sérgio M Morgado, Fernanda S Freitas, Nathalia S Bighi, Rosângela Cipriano, Ana Carolina Paulo Vicente
Background: Pandrug-resistant (PDR) Klebsiella pneumoniae has been reported sporadically in many countries and remains rare in Brazil.
Objectives: This study unravelled the genetic determinants involved with the PDR background of a clinical ST11 K. pneumoniae recovered in the Brazilian Amazon Region, where K. pneumoniae genomic and epidemiological information is scarce.
Methods: Kp196 was submitted to the antimicrobial susceptibility test by the disk-diffusion method and minimum inhibitory concentration (MIC) determination. The whole genome sequencing was obtained and the sequence type was determined by core genome multilocus sequence typing (cgMLST). Its intrinsic and acquired resistome was assessed by Comprehensive Antibiotic Resistance Database (CARD) and comparison with wild-type genes.
Findings: The analyses revealed that Kp196 belonged to the pandemic ST11 and presented the PDR phenotype. Its acquired resistome was composed of a huge set of clinically relevant resistance determinants, including bla CTX-M-15 and bla NDM-1, all found in the vicinity of mobile platforms. Considering its intrinsic resistome, the multidrug resistance, especially to colistin, tigecycline and fluoroquinolones, was multifactorial and attributed to modifications (indels, missense mutations, and gene disruption) in several housekeeping genes (arnT/phoQ/mgrB/ramR/acrB/gyrA/parC/ompK35-36-37). The Kp196 intrinsic resistome was also observed in a ST11 environmental strain, although harbouring distinct acquired resistomes.
Conclusions: An accumulation of different resistance mechanisms regarding the intrinsic resistome accounts for a more stable resistome, strongly contributing to the Kp196 PDR phenotype.
{"title":"Unveiling the genome of a high-risk pandrug-resistant Klebsiella pneumoniae emerging in the Brazilian Amazon Region, 2022.","authors":"Érica Lourenço Fonseca, Sérgio M Morgado, Fernanda S Freitas, Nathalia S Bighi, Rosângela Cipriano, Ana Carolina Paulo Vicente","doi":"10.1590/0074-02760230081","DOIUrl":"10.1590/0074-02760230081","url":null,"abstract":"<p><strong>Background: </strong>Pandrug-resistant (PDR) Klebsiella pneumoniae has been reported sporadically in many countries and remains rare in Brazil.</p><p><strong>Objectives: </strong>This study unravelled the genetic determinants involved with the PDR background of a clinical ST11 K. pneumoniae recovered in the Brazilian Amazon Region, where K. pneumoniae genomic and epidemiological information is scarce.</p><p><strong>Methods: </strong>Kp196 was submitted to the antimicrobial susceptibility test by the disk-diffusion method and minimum inhibitory concentration (MIC) determination. The whole genome sequencing was obtained and the sequence type was determined by core genome multilocus sequence typing (cgMLST). Its intrinsic and acquired resistome was assessed by Comprehensive Antibiotic Resistance Database (CARD) and comparison with wild-type genes.</p><p><strong>Findings: </strong>The analyses revealed that Kp196 belonged to the pandemic ST11 and presented the PDR phenotype. Its acquired resistome was composed of a huge set of clinically relevant resistance determinants, including bla CTX-M-15 and bla NDM-1, all found in the vicinity of mobile platforms. Considering its intrinsic resistome, the multidrug resistance, especially to colistin, tigecycline and fluoroquinolones, was multifactorial and attributed to modifications (indels, missense mutations, and gene disruption) in several housekeeping genes (arnT/phoQ/mgrB/ramR/acrB/gyrA/parC/ompK35-36-37). The Kp196 intrinsic resistome was also observed in a ST11 environmental strain, although harbouring distinct acquired resistomes.</p><p><strong>Conclusions: </strong>An accumulation of different resistance mechanisms regarding the intrinsic resistome accounts for a more stable resistome, strongly contributing to the Kp196 PDR phenotype.</p>","PeriodicalId":18469,"journal":{"name":"Memorias do Instituto Oswaldo Cruz","volume":"118 ","pages":"e230081"},"PeriodicalIF":2.8,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626633/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71424881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-23eCollection Date: 2023-01-01DOI: 10.1590/0074-02760220295
Leyllane Rafael Moreira, Ana Carla Silva, Cíntia Nascimento da Costa Oliveira, Claudeir Dias da Silva Júnior, Amanda Vasconcelos Nascimento, Kamila Kássia Dos Santos Oliveira, Ana Karine de Araújo Soares, Karina Lidianne Alcântara Saraiva, Milena de Paiva Cavalcanti, Virginia Maria Barros de Lorena
Background: Trypanosoma cruzi, which causes Chagas disease (CD), is a versatile haemoparasite that uses several strategies to evade the host's immune response, including adipose tissue (AT), used as a reservoir of infection. As it is an effective barrier to parasite evasion, the effectiveness of the drug recommended for treating CD, Benznidazole (BZ), may be questionable.
Objective: To this end, we evaluated the parasite load and immunomodulation caused by BZ treatment in the culture of adipocytes differentiated from human adipose tissue-derived stem cells (ADSC) infected with T. cruzi.
Methods: The ADSC were subjected to adipogenic differentiation. We then carried out four cultures in which we infected the differentiated AT with trypomastigote forms of the Y strain of T. cruzi and treated them with BZ. After the incubation, the infected AT was subjected to quantitative polymerase chain reaction (qPCR) to quantify the parasite load and transmission electron microscopy (TEM) to verify the infection. The supernatant was collected to measure cytokines, chemokines, and adipokines.
Findings: We found elevated secretion of IL-6, CXCL-10/IP-10, CCL2/MCP-1, CCL5/RANTES, and leptin in infected fat cells. However, treatment with BZ promoted a decrease in IL-6.
Main conclusion: Therefore, we believe that BZ has a beneficial role as it reduces inflammation in infected fat cells.
{"title":"Benznidazole treatment decreases IL-6 levels in Trypanosoma cruzi-infected human adipocytes differentiated from adipose tissue-derived stem cells.","authors":"Leyllane Rafael Moreira, Ana Carla Silva, Cíntia Nascimento da Costa Oliveira, Claudeir Dias da Silva Júnior, Amanda Vasconcelos Nascimento, Kamila Kássia Dos Santos Oliveira, Ana Karine de Araújo Soares, Karina Lidianne Alcântara Saraiva, Milena de Paiva Cavalcanti, Virginia Maria Barros de Lorena","doi":"10.1590/0074-02760220295","DOIUrl":"10.1590/0074-02760220295","url":null,"abstract":"<p><strong>Background: </strong>Trypanosoma cruzi, which causes Chagas disease (CD), is a versatile haemoparasite that uses several strategies to evade the host's immune response, including adipose tissue (AT), used as a reservoir of infection. As it is an effective barrier to parasite evasion, the effectiveness of the drug recommended for treating CD, Benznidazole (BZ), may be questionable.</p><p><strong>Objective: </strong>To this end, we evaluated the parasite load and immunomodulation caused by BZ treatment in the culture of adipocytes differentiated from human adipose tissue-derived stem cells (ADSC) infected with T. cruzi.</p><p><strong>Methods: </strong>The ADSC were subjected to adipogenic differentiation. We then carried out four cultures in which we infected the differentiated AT with trypomastigote forms of the Y strain of T. cruzi and treated them with BZ. After the incubation, the infected AT was subjected to quantitative polymerase chain reaction (qPCR) to quantify the parasite load and transmission electron microscopy (TEM) to verify the infection. The supernatant was collected to measure cytokines, chemokines, and adipokines.</p><p><strong>Findings: </strong>We found elevated secretion of IL-6, CXCL-10/IP-10, CCL2/MCP-1, CCL5/RANTES, and leptin in infected fat cells. However, treatment with BZ promoted a decrease in IL-6.</p><p><strong>Main conclusion: </strong>Therefore, we believe that BZ has a beneficial role as it reduces inflammation in infected fat cells.</p>","PeriodicalId":18469,"journal":{"name":"Memorias do Instituto Oswaldo Cruz","volume":"118 ","pages":"e220295"},"PeriodicalIF":2.8,"publicationDate":"2023-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50162134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-20eCollection Date: 2023-01-01DOI: 10.1590/0074-02760230116
Bruna de Paula Fonseca, Carlos Medicis Morel
Background: The Global Virome Project (GVP) was proposed in 2018 as an evolution of the USAID PREDICT project and was presented as a "collaborative scientific initiative to discover zoonotic viral threats and stop future pandemics". The immediate response was mixed, with public health and scientific communities representatives showing skepticism, if not direct opposition.
Objectives: The economic, social, and health consequences of the coronavirus disease 2019 (COVID-19) pandemic demonstrated how unprepared the world was in the face of new pandemics. This paper analyses the impact of the GVP on the scientific and public health communities.
Methods: Published scientific articles that cited the two 2018 seminal publications proposing the project were analysed using social network analysis methods.
Findings: Encompassing the periods before and after the onset of the Covid-19 pandemic, the results indicate that (i) the concepts of the GVP have received more support than opposition in the scientific literature; (ii) its foundations should be updated to address the specific criticisms.
Main conclusions: Shifting focus to national virome projects can provide tangible, regional benefits that can positively contribute towards a consensus on achieving a high level of preparedness for the ever-present possibility of the following global viral pandemic.
{"title":"Relevance of national, regional and global virome projects on pandemics prediction, prevention, and control: a social network analysis of GVP-citing articles.","authors":"Bruna de Paula Fonseca, Carlos Medicis Morel","doi":"10.1590/0074-02760230116","DOIUrl":"10.1590/0074-02760230116","url":null,"abstract":"<p><strong>Background: </strong>The Global Virome Project (GVP) was proposed in 2018 as an evolution of the USAID PREDICT project and was presented as a \"collaborative scientific initiative to discover zoonotic viral threats and stop future pandemics\". The immediate response was mixed, with public health and scientific communities representatives showing skepticism, if not direct opposition.</p><p><strong>Objectives: </strong>The economic, social, and health consequences of the coronavirus disease 2019 (COVID-19) pandemic demonstrated how unprepared the world was in the face of new pandemics. This paper analyses the impact of the GVP on the scientific and public health communities.</p><p><strong>Methods: </strong>Published scientific articles that cited the two 2018 seminal publications proposing the project were analysed using social network analysis methods.</p><p><strong>Findings: </strong>Encompassing the periods before and after the onset of the Covid-19 pandemic, the results indicate that (i) the concepts of the GVP have received more support than opposition in the scientific literature; (ii) its foundations should be updated to address the specific criticisms.</p><p><strong>Main conclusions: </strong>Shifting focus to national virome projects can provide tangible, regional benefits that can positively contribute towards a consensus on achieving a high level of preparedness for the ever-present possibility of the following global viral pandemic.</p>","PeriodicalId":18469,"journal":{"name":"Memorias do Instituto Oswaldo Cruz","volume":"118 ","pages":"e230116"},"PeriodicalIF":2.8,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50162135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: The Bacille Calmette-Guérin (BCG) vaccine comprises a family of strains with variable protective efficacy against pulmonary tuberculosis (TB) and leprosy, partly due to genetic differences between strains.
Objectives: Previous data highlighting differences between the genomes and proteomic profiles of BCG strains Moreau and Pasteur led us to evaluate their behaviour in the macrophage microenvironment, capable of stimulating molecular responses that can impact the protective effect of the vaccine.
Methods: Strain infectivity, viability, co-localisation with acidified vesicles, macrophage secretion of IL-1 and MCP-1 and lipid droplet biogenesis were evaluated after infection.
Findings: We found that BCG Moreau is internalised more efficiently, with significantly better intracellular survival up to 96 h p.i., whereas more BCG Pasteur bacilli were found co-localised in acidified vesicles up to 6 h p.i. IL-1β and MCP-1 secretion and lipid droplet biogenesis by infected macrophages were more prominent in response to BCG Pasteur.
Main conclusion: Overall, our results show that, compared to Pasteur, BCG Moreau has increased fitness and better endurance in the harsh intracellular environment, also regulating anti-microbial responses (lower IL-1b and MCP-1). These findings contribute to the understanding of the physiology of BCG Moreau and Pasteur in response to the intraphagosomal environment in a THP-1 macrophage model.
{"title":"Differences in responses to the intracellular macrophage environment between Mycobacterium bovis BCG vaccine strains Moreau and Pasteur.","authors":"Paloma Rezende Corrêa, Marcos Gustavo Araujo Schwarz, Renata Monteiro Maia, Fátima Maria Figueroa Vergara, Milton Ozório Moraes, Leila Mendonça-Lima","doi":"10.1590/0074-02760230070","DOIUrl":"10.1590/0074-02760230070","url":null,"abstract":"<p><strong>Background: </strong>The Bacille Calmette-Guérin (BCG) vaccine comprises a family of strains with variable protective efficacy against pulmonary tuberculosis (TB) and leprosy, partly due to genetic differences between strains.</p><p><strong>Objectives: </strong>Previous data highlighting differences between the genomes and proteomic profiles of BCG strains Moreau and Pasteur led us to evaluate their behaviour in the macrophage microenvironment, capable of stimulating molecular responses that can impact the protective effect of the vaccine.</p><p><strong>Methods: </strong>Strain infectivity, viability, co-localisation with acidified vesicles, macrophage secretion of IL-1 and MCP-1 and lipid droplet biogenesis were evaluated after infection.</p><p><strong>Findings: </strong>We found that BCG Moreau is internalised more efficiently, with significantly better intracellular survival up to 96 h p.i., whereas more BCG Pasteur bacilli were found co-localised in acidified vesicles up to 6 h p.i. IL-1β and MCP-1 secretion and lipid droplet biogenesis by infected macrophages were more prominent in response to BCG Pasteur.</p><p><strong>Main conclusion: </strong>Overall, our results show that, compared to Pasteur, BCG Moreau has increased fitness and better endurance in the harsh intracellular environment, also regulating anti-microbial responses (lower IL-1b and MCP-1). These findings contribute to the understanding of the physiology of BCG Moreau and Pasteur in response to the intraphagosomal environment in a THP-1 macrophage model.</p>","PeriodicalId":18469,"journal":{"name":"Memorias do Instituto Oswaldo Cruz","volume":"118 ","pages":"e230070"},"PeriodicalIF":2.8,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49679342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-13eCollection Date: 2023-01-01DOI: 10.1590/0074-02760230069
Otávio Espíndola, Paola C Resende, Lusiele Guaraldo, Guilherme Amaral Calvet, Trevon L Fuller, Stephanie Lema Suarez Penetra, Heloisa Ferreira Pinto Santos, Anielle Pina-Costa, Michele Fernanda Borges da Silva, Isabella Campos Vargas Moraes, Fernando Medeiros, Jimmy Whitworth, Christopher Smith, Karin Nielsen-Saines, Marilda M Siqueira, Patrícia Brasil
Background: There is interest in lingering non-specific symptoms after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, referred to as Long coronavirus disease 2019 (Long COVID-19). It remains unknown whether the risk of Long COVID-19 is associated with pre-existing comorbidities or initial COVID-19 severity, including infections due to new Omicron lineages which predominated in 2023.
Objectives: The aim of this case report was to characterize the clinical features of acute XBB.1.5 infection followed by Long COVID-19.
Methods: We followed a 73-year old female resident of Rio de Janeiro with laboratory-confirmed SARS-CoV-2 during acute infection and subsequent months. The SARS-CoV-2 lineage was determined by genome sequencing.
Findings: The participant denied comorbidities and had completed a two-dose vaccination schedule followed by two booster doses eight months prior to SARS-CoV-2 infection. Primary infection by viral lineage XBB.1.5. was clinically mild, but the participant subsequently reported persistent fatigue.
Main conclusions: This case demonstrates that Long COVID-19 may develop even after mild disease due to SARS-CoV-2 in fully vaccinated and boosted individuals without comorbidities. Continued monitoring of new SARS-CoV-2 lineages and associated clinical outcomes is warranted. Measures to prevent infection should continue to be implemented including development of new vaccines and antivirals effective against novel variants.
{"title":"Long COVID-19 syndrome associated with Omicron XBB.1.5 infection: a case report.","authors":"Otávio Espíndola, Paola C Resende, Lusiele Guaraldo, Guilherme Amaral Calvet, Trevon L Fuller, Stephanie Lema Suarez Penetra, Heloisa Ferreira Pinto Santos, Anielle Pina-Costa, Michele Fernanda Borges da Silva, Isabella Campos Vargas Moraes, Fernando Medeiros, Jimmy Whitworth, Christopher Smith, Karin Nielsen-Saines, Marilda M Siqueira, Patrícia Brasil","doi":"10.1590/0074-02760230069","DOIUrl":"10.1590/0074-02760230069","url":null,"abstract":"<p><strong>Background: </strong>There is interest in lingering non-specific symptoms after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, referred to as Long coronavirus disease 2019 (Long COVID-19). It remains unknown whether the risk of Long COVID-19 is associated with pre-existing comorbidities or initial COVID-19 severity, including infections due to new Omicron lineages which predominated in 2023.</p><p><strong>Objectives: </strong>The aim of this case report was to characterize the clinical features of acute XBB.1.5 infection followed by Long COVID-19.</p><p><strong>Methods: </strong>We followed a 73-year old female resident of Rio de Janeiro with laboratory-confirmed SARS-CoV-2 during acute infection and subsequent months. The SARS-CoV-2 lineage was determined by genome sequencing.</p><p><strong>Findings: </strong>The participant denied comorbidities and had completed a two-dose vaccination schedule followed by two booster doses eight months prior to SARS-CoV-2 infection. Primary infection by viral lineage XBB.1.5. was clinically mild, but the participant subsequently reported persistent fatigue.</p><p><strong>Main conclusions: </strong>This case demonstrates that Long COVID-19 may develop even after mild disease due to SARS-CoV-2 in fully vaccinated and boosted individuals without comorbidities. Continued monitoring of new SARS-CoV-2 lineages and associated clinical outcomes is warranted. Measures to prevent infection should continue to be implemented including development of new vaccines and antivirals effective against novel variants.</p>","PeriodicalId":18469,"journal":{"name":"Memorias do Instituto Oswaldo Cruz","volume":"118 ","pages":"e230069"},"PeriodicalIF":2.8,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49679343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-09eCollection Date: 2023-01-01DOI: 10.1590/0074-02760230044
Suelen Silva Gomes Dias, Tamires Cunha-Fernandes, Vinicius Cardoso Soares, Cecília Jg de Almeida, Patricia T Bozza
Lipid droplets (LD) are evolutionarily conserved lipid-enriched organelles with a diverse array of cell- and stimulus-regulated proteins. Accumulating evidence demonstrates that intracellular pathogens exploit LD as energy sources, replication sites, and part of the mechanisms of immune evasion. Nevertheless, LD can also favor the host as part of the immune and inflammatory response to pathogens. The functions of LD in the central nervous system have gained great interest due to their presence in various cell types in the brain and for their suggested involvement in neurodevelopment and neurodegenerative diseases. Only recently have the roles of LD in neuroinfections begun to be explored. Recent findings reveal that lipid remodelling and increased LD biogenesis play important roles for Zika virus (ZIKV) replication and pathogenesis in neural cells. Moreover, blocking LD formation by targeting DGAT-1 in vivo inhibited virus replication and inflammation in the brain. Therefore, targeting lipid metabolism and LD biogenesis may represent potential strategies for anti-ZIKV treatment development. Here, we review the progress in understanding LD functions in the central nervous system in the context of the host response to Zika infection.
{"title":"Lipid droplets in Zika neuroinfection: Potential targets for intervention?","authors":"Suelen Silva Gomes Dias, Tamires Cunha-Fernandes, Vinicius Cardoso Soares, Cecília Jg de Almeida, Patricia T Bozza","doi":"10.1590/0074-02760230044","DOIUrl":"https://doi.org/10.1590/0074-02760230044","url":null,"abstract":"<p><p>Lipid droplets (LD) are evolutionarily conserved lipid-enriched organelles with a diverse array of cell- and stimulus-regulated proteins. Accumulating evidence demonstrates that intracellular pathogens exploit LD as energy sources, replication sites, and part of the mechanisms of immune evasion. Nevertheless, LD can also favor the host as part of the immune and inflammatory response to pathogens. The functions of LD in the central nervous system have gained great interest due to their presence in various cell types in the brain and for their suggested involvement in neurodevelopment and neurodegenerative diseases. Only recently have the roles of LD in neuroinfections begun to be explored. Recent findings reveal that lipid remodelling and increased LD biogenesis play important roles for Zika virus (ZIKV) replication and pathogenesis in neural cells. Moreover, blocking LD formation by targeting DGAT-1 in vivo inhibited virus replication and inflammation in the brain. Therefore, targeting lipid metabolism and LD biogenesis may represent potential strategies for anti-ZIKV treatment development. Here, we review the progress in understanding LD functions in the central nervous system in the context of the host response to Zika infection.</p>","PeriodicalId":18469,"journal":{"name":"Memorias do Instituto Oswaldo Cruz","volume":"118 ","pages":"e230044"},"PeriodicalIF":2.8,"publicationDate":"2023-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566564/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41204764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}